Corporate governance in Diamyd Medical AB is based on the Swedish Companies Act and other relevant rules and recommendations for public companies.

In accordance with the Swedish Companies Act, the General Meeting is Diamyd Medical’s supreme decision-making body. At the General Meeting, shareholders may exercise their voting rights in key issues, for example the adoption of profit and loss statements and balance sheets, the allocation of the Company's profit, the granting of discharge from liability to the Board of Directors and CEO, the election of members of the Board of Directors and auditors, and fees to the Board of Directors and auditors.
Documents are available in Swedish only.

General Meeting Documents

Kallelse till årsstämma 5 december 2024


Villkor för teckningsoptioner 2024-2028


Årsstämmoprotokoll 2024


The Nomination Committee of Diamyd Medical AB consists of the two largest shareholders:
Anders Essen-Möller and Bertil Lindqvist.

E-mails to the Nomination Committee:
Diamyd Medical’s auditor is BDO AB with Johan Pharmanson as the principal auditor.
The information below is related to previous rights issues in Diamyd Medical and are not to be regarded as public offers. Documents are available in Swedish only.
Prospekt - Företrädesemission i Diamyd Medical AB (publ), oktober 2023

Tilläggsprospekt, oktober 2023

Prospekt - Företrädesemission i Diamyd Medical AB (publ), juni 2023

Tilläggsprospekt, juni 2023

Prospekt - Företrädesemission i Diamyd Medical AB (publ) 2017

Articles of Incorporation

Articles of Incorporation for Diamyd Medical AB adopted at an Extra General Meeting of Shareholders on June 26, 2023.

   Bolagsordning  

Order GAD for preclinical research

GAD PRODUCTS